AU2002255705A8 - Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain - Google Patents

Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain

Info

Publication number
AU2002255705A8
AU2002255705A8 AU2002255705A AU2002255705A AU2002255705A8 AU 2002255705 A8 AU2002255705 A8 AU 2002255705A8 AU 2002255705 A AU2002255705 A AU 2002255705A AU 2002255705 A AU2002255705 A AU 2002255705A AU 2002255705 A8 AU2002255705 A8 AU 2002255705A8
Authority
AU
Australia
Prior art keywords
hypoxia
prevention
treatment
neuropathic pain
neuroactive peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002255705A
Other versions
AU2002255705A1 (en
Inventor
Joseph R Moskal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NYXIS Neuro Therapies Inc
Original Assignee
NYXIS Neuro Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NYXIS Neuro Therapies Inc filed Critical NYXIS Neuro Therapies Inc
Publication of AU2002255705A1 publication Critical patent/AU2002255705A1/en
Publication of AU2002255705A8 publication Critical patent/AU2002255705A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002255705A 2001-03-12 2002-03-12 Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain Abandoned AU2002255705A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27508301P 2001-03-12 2001-03-12
US60/275,083 2001-03-12
PCT/US2002/007427 WO2002072609A2 (en) 2001-03-12 2002-03-12 Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain

Publications (2)

Publication Number Publication Date
AU2002255705A1 AU2002255705A1 (en) 2002-09-24
AU2002255705A8 true AU2002255705A8 (en) 2010-02-11

Family

ID=23050810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002255705A Abandoned AU2002255705A1 (en) 2001-03-12 2002-03-12 Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain

Country Status (2)

Country Link
AU (1) AU2002255705A1 (en)
WO (1) WO2002072609A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (en) 2008-09-18 2011-11-18 Univ Northwestern Nmda receptor modulators and uses thereof.
US20120178695A1 (en) * 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9101612B2 (en) 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP6531042B2 (en) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド Spirolactam NMDA receptor modulators and uses thereof
HRP20221545T1 (en) 2013-01-29 2023-03-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009778A (en) 2013-01-29 2016-02-09 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof.
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP6823083B2 (en) 2016-05-19 2021-01-27 アプティニックス インコーポレイテッド Spirolactam NMDA Receptor Modulators and Their Use
MX2019001318A (en) 2016-08-01 2019-07-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof.
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
IL264496B (en) 2016-08-01 2022-09-01 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (en) 2016-08-01 2019-04-10 Aptinyx Inc NMDA ESPIRO-LACTAM MODULATORS AND METHODS OF USE OF THE SAME
BR112019001768A2 (en) 2016-08-01 2019-06-11 Aptinyx Inc spiro-lactam receptor modulators and their uses
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Also Published As

Publication number Publication date
WO2002072609A2 (en) 2002-09-19
AU2002255705A1 (en) 2002-09-24
WO2002072609A9 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
AU2002255705A8 (en) Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
TWI347188B (en) Treatment and prevention of osteoporosis
EP1399171A4 (en) Medicinal herbal compounds for the prevention and treatment of diabetes
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
EP1461024A4 (en) Treatment of wounds and compositions employed
AU2002247004A1 (en) Methods of diagnosis and treatment of osteoporosis
HUP0400005A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
HUP0400119A3 (en) Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite
PL362920A1 (en) Therapeutic film forming composition and treatment system
EP1356812A4 (en) Medicines for treatment and prevention of neurogenic pain
AU2002364171A8 (en) Materials and methods for the treatment or prevention of obesity
SI1462455T1 (en) Ser-Ser-Ser-Arg peptide and medicinal uses thereof
AU3898000A (en) Treatment of neuropathic pain or fibromyalgia
AU2003231279A8 (en) Prevention and treatment of type 2 diabetes
GB0101146D0 (en) Treatment of skin conditions
EP1250145A4 (en) C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
EP1409734A4 (en) Diagnosis and treatment of cancer
GB2381272B (en) Diagnosis and treatment of atherosclerosis
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
EP1207895A4 (en) Peptide and peptide analogues for the treatment and prevention of diabetes
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
EP1457494A4 (en) Processes for preparation of sulphostin and its analogues or intermediates thereof
GB0100092D0 (en) Treatment of degenerative diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase